PET-FDG FOR BREAST CANCER IMAGING AND PROGNOSIS

PET-FDG 用于乳腺癌成像和预后

• 批准号: 2100480
• 负责人: LEE P ADLER
• 金额: $ 9.95万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-05-14 至 1998-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2100480
• 关键词: breast neoplasm /cancer diagnosis; breast neoplasms; carcinoma; clinical biomedical equipment; contrast media; deoxyglucose; diagnosis quality /standard; female; fluorine; human subject; lymph nodes; metastasis; noninvasive diagnosis; phantom model; positron emission tomography; prognosis; breast neoplasm /cancer diagnosis; breast neoplasms; carcinoma; clinical biomedical equipment; contrast media; deoxyglucose; diagnosis quality /standard; female; fluorine; human subject; lymph nodes; metastasis; noninvasive diagnosis; phantom model; positron emission tomography; prognosis

Positron emission tomography (PET) has been utilized to image several types of tumors in vivo. PET has the advantage of providing functional information not obtainable with anatomic imaging modalities, such as mammography, ultrasound and magnetic resonance imaging. When used in conjunction with the glucose analog [fluorine-18] 2-deoxy-2-fluoro-D-glucose (FDG), PET has shown a high correlation with histological grade in tumors of the brain and musculoskeletal system. FDG uptake by astrocytomas correlates inversely with patient survival. Recently, PET-FDG has successfully imaged both primary breast carcinomas and axillary node metastases. Preliminary data demonstrate a significant difference in FDG uptake between benign and malignant breast lesions. There is a moderate correlation between FDG uptake in the primary malignancies and the presence of lymph nodes as detected by axillary node dissection. As treatment for breast cancer is determined by individual relapse risk, there is a need for more accurate stratification of patients into risk categories. Currently, the presence or absence of axillary nodal disease is the single most important prognostic factor. To make this determination from axillary node dissection has attendant costs and morbidity. This proposal seeks funding to study 100 women who have solid breast masses with PET-FDG prior to surgery. This study will assess the ability of PET-FDG to discriminate between benign and malignant breast lesions. The accuracy of PET-FDG at predicting the presence or absence of axillary node metastases as determined by axillary node dissection will be assessed. Finally, the uptake of FDG will be compared with patient survival statistics to determine if FDG uptake may be a strong prognostic factor for patient survival. If PET-FDG demonstrates new prognostic information for breast cancer, it will have profound implications on patient management.

正电子发射断层扫描（PET）已被用于成像几个 体内肿瘤的类型。 宠物的优势是提供功能 通过解剖成像方式无法获得的信息，例如 乳房X线摄影，超声和磁共振成像。 使用时 与葡萄糖类似物的结合[氟-18] 2-脱氧-2-氟-d-葡萄糖（FDG），PET与 大脑肿瘤和肌肉骨骼系统的组织学等级。 星形胶质细胞瘤的FDG摄取与患者的存活相关。 最近，PET-FDG成功成像了两个原发性乳腺癌 和腋节结节转移。 初步数据证明了重要的 良性和恶性乳房病变之间FDG摄取的差异。 初级的FDG吸收之间存在适度的相关性 腋窝淋巴结检测到的恶性肿瘤和淋巴结的存在 解剖。 因为乳腺癌的治疗是由个体确定的 复发风险，需要更准确地分层 患者分类。 目前，存在或不存在 腋窝结节疾病是最重要的预后因素。 为了从腋窝剖析中确定这一确定 成本和发病率。 该提议寻求资金来研究100名具有坚实乳房的女性 手术前患有PET-FDG的质量。 这项研究将评估能力 PET-FDG的区分良性和恶性乳房病变。 PET-FDG预测存在或不存在腋窝的准确性 由腋窝剖析确定的节点转移将是 评估。 最后，将FDG的摄取与患者进行比较 生存统计数据以确定FDG摄取是否可能是强烈的预后 患者生存的因素。 如果PET-FDG展示了新的预后 乳腺癌的信息将对 患者管理。